-+ 0.00%
-+ 0.00%
-+ 0.00%

United Therapeutics says FDA accepts Tyvaso sNDA for idiopathic pulmonary fibrosis review

PUBT·09/02/2026 11:01:07
Listen to the news
United Therapeutics says FDA accepts Tyvaso sNDA for idiopathic pulmonary fibrosis review
  • United Therapeutics’ FDA accepted an sNDA for nebulized Tyvaso to treat idiopathic pulmonary fibrosis.
  • Agency action starts a review targeted for completion in late April 2027.
  • Filing supported by Phase 3 TETON-1 and TETON-2 data showing a 111.8 mL FVC benefit versus placebo at week 52.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202609020700BIZWIRE_USPR_____20260902_BW138059) on September 02, 2026, and is solely responsible for the information contained therein.